ArticleOncotarget2016

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

C Willemien Menke-van der Houven van Oordt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.